Perindopril litigation: Lupin may have to pay over Rs 325 crore fine

New Delhi: Drug maker Lupin recently said a court in Europe has upheld a decision to impose a fine of 40 million euros (over Rs 325 crore) on the company by European Commission (EC) in a litigation over blood pressure lowering drug Perindopril.

The Mumbai-based company said the General Court of the European Union has delivered its judgment concerning Lupin's and other companies appeal against the EC 2014 decision in the Perindopril litigation.

"The General Court upheld the EC's decision holding Lupin liable to pay a fine of euro 40 million," the company said in a regulatory filing. The company added that it will study the court's judgment and evaluate the further course of action.

In 2014, Lupin and Unichem Laboratories are among six global drug makers on which the European regulator had imposed a collective fine of 427.7 million euros for striking deals to prevent entry of cheaper version of blood pressure drug Perindopril in the EU.

Also Read: After 12 years of service, Lupin Chief Financial Officer quits to pursue non pharma opportunities